Treatment of *Cryptosporidium*: What We Know, Gaps, and the Way Forward

Hayley Sparks¹ · Gayatri Nair¹ · Alejandro Castellanos-Gonzalez¹ ·
A. Clinton White Jr.¹

Published online: 1 August 2015
© Springer International Publishing AG 2015

Abstract Cryptosporidiosis is increasingly recognized as an important global health concern. While initially reported in immunocompromised patients such as AIDS patients, cryptosporidiosis has now been documented as a major cause of childhood diarrhea and an important factor in childhood malnutrition. Currently, nitazoxanide is the only proven anti-parasitic treatment for *Cryptosporidium* infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants. Immune reconstitution or decreased immunosuppression is critical to therapy in AIDS and transplant patients. This limitation of treatment options presents a major public health challenge given the important burden of disease. Repurposing of drugs developed for other indications and development of inhibitors for novel targets offer hope for improved therapies, but none have advanced to clinical studies.

Keywords *Cryptosporidium* · *Cryptosporidium parvum* · *Cryptosporidium hominis* · Cryptosporidiosis · Nitazoxanide · Paromomycin

Introduction

Cryptosporidium species are increasingly recognized as important enteric pathogens [1, 2•, 3]. Cryptosporidiosis was initially recognized as a cause of diarrhea in compromised hosts. Shortly thereafter, zoonotic and waterborne transmission of the parasite was identified. *Cryptosporidium* is now considered one of the major causes of childhood diarrhea. In addition, *Cryptosporidium* has been documented as a key component of the vicious cycle of infection and malnutrition that are major contributors to childhood morbidity and mortality worldwide. The majority of human *Cryptosporidium* infections are attributed to two species: *Cryptosporidium hominis* and *Cryptosporidium parvum* [1, 2•]. However, at least 13 other species may infect humans [3–5]. Clinically, cryptosporidiosis causes watery diarrhea in healthy patients. In contrast to other causes, diarrhea caused by cryptosporidiosis tends to be more prolonged and can be chronic in compromised hosts, such as children with malnutrition (Table 1).

Cryptosporidium parasites develop within the microvillus layer of intestinal epithelial cells, mainly found in the small intestines in immunocompetent hosts, but may be found throughout the GI tract and even the respiratory tract. Persistent infection is associated with villus atrophy, crypt hyperplasia, and variable increases in leucocytes in the lamina propria. The symptoms of watery diarrhea and malabsorption are thought to be related to sodium malabsorption, electrogenic chloride secretion, and increased intestinal permeability, and severity of disease correlates with altered intestinal permeability [6, 7]. These effects are likely mediated by the host

This article is part of the Topical Collection on *Protozoa*

✉ A. Clinton White, Jr.
acwhite@utmb.edu

Hayley Sparks
hnsparks@utmb.edu

Gayatri Nair
gvnair@utmb.edu

Alejandro Castellanos-Gonzalez
alcastel@utmb.edu

¹ Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch Galveston, 301 University Boulevard, Route 0435, Galveston, TX 77555-0435, USA

Table 1 Current and prospective therapeutic options for *Cryptosporidium* infection

	Therapeutics	Research level	Comments
Current therapeutics	Nitazoxanide	FDA approved for treatment of patients 1 year and older	Not useful in patients with AIDS
	Nitazoxanide/ azithromycin/ paromomycin mixtures	Anecdotal clinical evidence of response in transplant patients	
	CD40 agonist antibody	One clinical study published	Patients relapsed after cessation of treatment
	Paromomycin	Multiple clinical studies	Clinical results have been mixed or moderate at best
	Azithromycin	One published clinical study	Decreases parasite load with clearance in some patients
Prospective therapeutics	Rifamycins (rifabutin, rifaximin)	Several clinical studies which included AIDS patients	Prevented infection in AIDS patients
	CDPK inhibitors	Several published in vitro and in vivo studies	
	N-Methyl-piperazine-Phe-homoPhe-vinylsulfonephenyl (K11777)	Published in vivo studies	Inhibits clan CA cysteine proteases
	Phylomer® peptides	Published in vitro studies	Inhibits <i>Cp</i> IMPDPH
	Compounds from NIH Clinical Collections	Published in vitro studies	Two compounds from this collection have been tested
	Malaria box drug-like compounds	One published in vitro study	
	Auronofin and other “orphan drugs”	Several published in vitro studies	Auranofin has been successfully tested against other apicomplexans in vivo

response and neuropeptides such as substance P may be key contributors [8, 9].

The burden of disease caused by *Cryptosporidium* worldwide has been significantly underestimated. For example, only about 1 % of the estimated 750,000 cases that occur annually in the US are reported [10, 11]. Historically, *Cryptosporidium* was thought of primarily as a cause of chronic diarrhea in AIDS and other immunocompromised patients. More recent data has shed light on the parasite's effect on children in resource-poor areas. Older studies, using acid fast staining to identify the organisms, found *Cryptosporidium* in <5 % of cases of childhood diarrhea. However, more recent studies using antigen and molecular assay have detected *Cryptosporidium* infection in 15–20 % of all childhood diarrhea [1, 12]. In a multicenter study of childhood diarrhea in Sub-Saharan Africa and South Asia, *Cryptosporidium* was second to rotavirus as a cause of moderate-to-severe diarrhea in children 2 years of age and was a major cause of morbidity in the second year of life [13••]. Subsequent studies using molecular methods demonstrated that even that study had underdiagnosed cryptosporidiosis [14••].

There are also chronic sequelae of *Cryptosporidium* infection. Lima et al. showed that infection in children less than

1 year old was followed by recurrent diarrhea and growth stunting that continued for 2 years after the initial episode [15]. Follow-up studies demonstrated deficits in cognitive development and physical fitness when patients were examined 5 years later [16].

Cryptosporidiosis is more frequent and severe disease in children with malnutrition, including higher incidence of deaths [2•, 17, 18]. Malnutrition predisposes patients to infection and creates a vicious infection-malnutrition cycle with long-term consequences including cognitive impairment and stunting [19]. Using an animal model that closely resembles the complex interaction between nutritional status and infection, Costa et al. showed 20 % additional weight loss when malnourished mice were infected with *C. parvum*, higher fecal shedding and failure to prevent weight loss, or parasite stool shedding despite treatment with nitazoxanide [20]. In addition, children under the age of 1 year with *Cryptosporidium* infections fail to have catch-up growth that is typically observed with children infected at a later age. The diarrheal morbidity for this young age group is significantly increased as well [18, 21].

Symptomatic therapy is vital in cases of cryptosporidiosis. Replacement of fluids and electrolytes in cryptosporidiosis is

critically important as in other causes of diarrhea. Antimotility drugs are also a key element of therapy. Most published patient studies utilize narcotic agents such as loperamide and diphenoxylate/atropine. Other reports suggest that tincture of opium (paregoric) may be a more effective agent in AIDS patients. Nutritional support is also imperative for successful treatment, which includes continued breastfeeding of infant patients.

Because cryptosporidiosis is typically self-limited in immunocompetent hosts, restoration of immune function is a key component of management. Immune reconstitution in response to effective combination antiretroviral therapy has been linked to parasite clearance, as well as reduced long-term morbidity and mortality associated with cryptosporidial infection of AIDS patients [20, 22, 23]. Nevertheless, even with effective antiretroviral therapy, chronic diarrhea is associated with early mortality [24]. There are anecdotes of better responses when anti-motility and anti-parasitic drugs are used as part of the initial therapy [23]. However, there is no conclusive evidence that this is the case. Interestingly, some HIV protease inhibitors have activity against *Cryptosporidium* both in vitro and in vivo [25].

Current Therapeutics

Despite the fact that cryptosporidiosis has been recognized as an important cause of diarrheal disease for over three decades, anti-parasitic treatments have been limited. Initial screening of available compounds failed to identify effective treatments for cryptosporidiosis. A number of drugs previously reported to be effective have failed in clinical trials [22].

The only drug that has FDA approval for treatment of *Cryptosporidium* is nitazoxanide [20]. Nitazoxanide was synthesized in the 1980s by combining a thiazole ring (similar structurally to metronidazole) with a benzamidine ring (similar to the tapeworm drug niclosamide). Nitazoxanide is a broad spectrum anti-parasitic with reports of use as a deworming agent as well as in controlled trials in giardiasis and cryptosporidiosis [22]. Three placebo-controlled trials of treatment of cryptosporidiosis with nitazoxanide in non-AIDS patients have been reported [26–28]. Studies reported up to 93 % of treated patients experienced parasite clearance as opposed to 37 % of placebo-treated patients [27]. The drug also has been shown to improve diarrhea and mortality rates among infected, malnourished children [26]. However, the response rate in malnourished children was only 56 % [26]. Unfortunately, nitazoxanide has not been found to be effective in AIDS patients [29].

Nitazoxanide is only FDA approved for patients 1 year of age or older. A recent study among hospitalized children in Egypt aged 6 months to 10 years presenting with persistent diarrhea compared paromomycin and

nitazoxanide with no antiparasitic treatment [30]. Overall, 86.6 % of children treated with 100 or 200 mg of nitazoxanide every 12 h for 3 days demonstrated complete clearance of oocysts and cessation of clinical symptoms. Among children treated with 25 mg/kg/day of paromomycin for 2 weeks, 68.8 % experienced stool clearance and were completely cured. Both treatments were better than no anti-parasitic treatment.

Though AIDS patients are the main immunocompromised population affected by *Cryptosporidium*, the parasite is also problematic in organ transplant recipients as well [31–33]. Bhaduria et al. conducted a retrospective review of living donor renal transplant recipients admitted for evaluation of diarrhea [33]. *Cryptosporidium* was found to be the most common cause of infectious diarrhea in these patients. Patients receiving combination immunosuppression including tacrolimus had higher rates of infection with *Cryptosporidium* compared to a combination of cyclosporine. Bhaduria and colleagues reported a better response to nitazoxanide/flouroquinolone combination therapy than to nitazoxanide alone [33]. However, the authors did not test the patients for *Escherichia coli* enteropathogens. Thus, the benefit of the fluoroquinolone may have been on undiagnosed bacterial co-infection. Other groups have noted that transplant patients responded poorly to nitazoxanide alone. Still, there are anecdotes of better responses to combinations of nitazoxanide, azithromycin, and/or paromomycin [34–36].

Another population affected by chronic *Cryptosporidium* infections includes patients with primary immunodeficiencies such as hyper-IgM syndrome. This syndrome is a combined immune deficiency disorder caused by mutations in CD40 ligand. Infections in these patients are similar to that of AIDS patients, with extra-intestinal manifestations including biliary involvement. Fan et al. showed that treatments with CD40 agonist antibody effectively reduced the number of oocytes shed by these patients. However, relapse occurred when treatment was stopped [37].

Physicians initially approached the devastating effects of cryptosporidiosis in AIDS patients by testing a wide range of available drugs. One such drug, paromomycin, was reported to ameliorate cryptosporidiosis in AIDS patients [38]. In neither of the two controlled trials in patients with AIDS were the effects more than modest (few cures and mild decrease in diarrhea) [38, 39]. In one controlled trial, there was a statistically significant decrease in oocyst shedding and diarrhea [40], while Hussien et al. demonstrated clearance of cryptosporidiosis among hospitalized children with paromomycin treatment compared to no treatment. However, the response was significantly less active than with nitazoxanide [30].

Other drugs reported to have some effect in case series include azithromycin, spiramycin, and bovine anti-cryptosporidium immunoglobulin [22]. However, all were ineffective in controlled trials in AIDS patients. Unfortunately,

while all of these studies were presented at scientific meetings, none of these trials have been published [22]. Azithromycin seemed to be better than two anthelmintic drugs for cryptosporidiosis in children [41]. It has also been used in combination with nitazoxanide and/or paromomycin in compromised hosts with decreased stool frequency and parasite clearance in some patients [34, 42].

Rifamycins have been studied for anti-*Cryptosporidium* activity. Rifabutin was tested in vitro and showed a 25 % decrease in *C. parvum* infection in vitro. When combined with nitazoxanide, infection decreased by 75 % [43]. Holmberg et al. [44] reported an 85 % decrease in the incidence of *Cryptosporidium* in the cohort of AIDS patients receiving rifabutin for *M. avium* complex prophylaxis, compared to the groups receiving clarithromycin or azithromycin. Similar results were seen when comparing AIDS patients taking rifabutin, clarithromycin, or a combination [45]. A small group of HIV patients were found to have resolution of diarrhea with rifaximin, a non-absorbed rifamycin [46, 47].

Gaps

While nitazoxanide was an important advance in the management of cryptosporidiosis in children, its limited efficacy in compromised or malnourished hosts has raised important questions regarding how to manage these patients. Clearly, we are in urgent need of better drugs for therapy of cryptosporidiosis. A pivotal step towards this goal is the identification of specific targets. At an experts' workshop on cryptosporidiosis, development of novel drugs for cryptosporidiosis was considered a critically important priority, with potentially huge public health payoffs. The inability to propagate the organisms in vitro or to genetically manipulate parasite gene expression were identified as major hurdles for drug development [2••].

Progress in developing novel drugs against *Cryptosporidium* also has been hampered by limitations of current experimental models [48]. Because animal models are suboptimal for some human infections, human cell lines have been used as an alternative to study intestinal pathogens [49, 50]. However, the utility of cell lines is limited by the fact they do not readily support parasite propagation. However, novel methods incorporating intestinal stem cells offer the prospect of significantly improving propagation [51].

Further hindrances in the research and treatment of *Cryptosporidium* are the gaps in understanding of the gastrointestinal and immune responses to the parasite. There is a specific lack of knowledge regarding the mechanisms of parasite clearance in immunocompetent hosts. Insight into this aspect of infection might enable advances in preventative research. A more in-depth knowledge of the gastrointestinal responses is also needed to facilitate optimization of current

treatment methods as well as provide specific targets for preventatives.

The Way Forward

One of the typical difficulties faced when developing anti-parasitic treatments is lack of drug targets that do not have human homologues. Several key enzymes have been identified as targets due to significant differences from human enzymes. Many apicomplexan parasites have unique calcium-dependent protein kinases, including the *Cryptosporidium* CDPK1, an essential component of cell invasion [52]. The parasites lack amino acids blocking access to the active site by “bumped kinase inhibitors”. Castellanos et al. have identified several compounds that bind to this enzyme, inhibiting enzyme function and ultimately killing the *Cryptosporidium* cell. A number of these inhibitors have exhibited anti-cryptosporidium activity both in vitro as well as in SCID-beige immunocompromised mouse models [53].

Clan CA cysteine proteases have been found to be a potential target for the treatment of cryptosporidiosis. Clan CA cysteine proteases are thought to be vital for host cell invasion and have been found to be structurally different than analogous enzymes in humans [54]. This protease can be inhibited utilizing *N*-methyl-piperazine-Phe-homoPhe-vinylsulfone phenyl (K11777) inhibits growth of *Cryptosporidium* in vitro and has been shown to rescue immunocompromised mice from lethal infection [55].

The folate biosynthesis pathway, historically a target for cancer, bacterial, and malarial disease, has also been identified as a potential target for anti-cryptosporidials. *Cryptosporidium* contains a bi-functional thymidylate synthase/dihydrofolate reductase enzyme. Licensed anti-bacterial and anti-protozoan drugs do not inhibit the cryptosporidium enzyme, but research teams are evaluating the activity of compounds designed to specifically block this key enzyme in the folate synthesis pathway in vitro. Published data has reported striking anti-cryptosporidial activity of these compounds within cell culture [56].

Another potential drug target is oxidoreductase inosine 5'-monophosphate dehydrogenase (IMPDH) which is essential in guanine synthesis in *Cryptosporidium*. Unlike human IMPDH, *Cp*IMPDH seems to have originated from bacteria via lateral gene transfer, thus the enzyme is structurally different than its human counterpart. Current research has found a series of inhibitors for this enzyme [57, 58]. Another study investigated the use of Phylomer® peptides to inhibit *Cp*IMPDH functions. These studies were conducted in vitro and identified two out of 12 peptides with anti-cryptosporidium functions [59].

The repurposing of already developed drugs or compounds is another promising area of anti-cryptosporidial research. A

study done by Bessoff et al. utilized Human HMG-CoA Reductase and Isoprenoid Synthesis inhibitors from the NIH Clinical Collections drug library in a novel cell-based assay [60]. Results showed that there may be a surprising amount of overlap between previously FDA approved drugs and potential anti-cryptosporidial activity [60]. The use of Malaria Box drug-like compounds is also being investigated. These compounds have been created by the Medicines for Malaria Venture and are freely available to researchers [61]. A preliminary study identified several potential anti-cryptosporidiosis candidates; however, further in vitro and in vivo research has yet to be published [62]. Similarly, the anti-inflammatory drug auranofin demonstrates activity against *Cryptosporidium* in vitro; however, no in vivo or clinical results have been published [63].

The re-evaluation of current oral rehydration therapies is also being conducted to determine its role in the clearance of *Cryptosporidium* in immunocompetent hosts. Castro et al. demonstrated that supplementation of L-arginine to infected, undernourished mice aided in weight gain and reduced parasite burden [64]. Similar findings were reported by Costa et al. and Argenzio et al. utilizing the supplementation of an oligodeoxynucleotide with unmethylated CpG motif, alanyl-glutamine, and tumor necrosis factor alpha in in vitro and in vivo models [65, 66]. These findings indicate that current recommended oral rehydration therapies may need to be updated; however, no clinical trials have been completed to assess these supplements in humans. Further research in this area could potentially provide a cost-effective treatment option for malnourished and immunocompromised patients in resource-limited areas.

Conclusions

Within the past few years, studies have increasingly focused on the importance of *Cryptosporidium* as a cause of childhood diarrhea and associated morbidity and mortality. However, there has been little clinical advancement in the treatment of cryptosporidiosis. The study conducted by Hussien et al. concluded that nitazoxanide treatment is superior to paromomycin in children with chronic diarrhea in endemic areas [30]. Successful development of novel drugs could also aid in decreasing childhood malnutrition. Progress has been slowed by limitation in methods to propagate the organisms in vitro and genetically manipulate the organisms. Nevertheless, research focused on anti-cryptosporidials continues to make substantial advancements. Several enzymes have been identified as potential drug targets, including calcium-dependent protein kinases [53], Clan CA cysteine proteases [55], IMPDH [57], and the folate biosynthesis pathway [56]. Other studies are testing compounds repurposed, which were

developed for other indications. However, none of these compounds have made it into clinical trials.

Compliance with Ethics Guidelines

Conflict of Interest Hayley Sparks, Gayatri Nair, and Alejandro Castellanos-Gonzalez declare that they have no conflict of interest.

A. Clinton White Jr receives royalties from UpToDate and Harrison's Internal Medicine for chapters on a different subject.

Human and Animal Rights and Informed Consent This article does not contain any studies with human subjects performed by any of the authors.

With regard to the authors' research cited in this paper, all institutional and national guidelines for the care and use of laboratory animals were followed.

References

Papers of particular interest, published recently, have been highlighted as:

•• Of major importance

1. White Jr AC. Cryptosporidiosis (*Cryptosporidium* species). In: Mandell D, editor. Bennett's principals and practices of infectious diseases. Philadelphia: Elsevier Saunders; 2015. p. 3173–83.e6.
2. •• Checkley W et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. *Lancet Infect Dis*. 2015;15(1):85–94. **This state of the art review came from a meeting of most of the leaders in the field to define the state-of-the art, gaps, and future research directions regarding epidemiology, diagnosis, treatment, and vaccination for cryptosporidiosis.**
3. Cama VA et al. Cryptosporidium species and subtypes and clinical manifestations in children, Peru. *Emerg Infect Dis*. 2008;14(10):1567–74.
4. Ryan U, Fayer R, Xiao L. Cryptosporidium species in humans and animals: current understanding and research needs. *Parasitology*. 2014;141(13):1667–85.
5. Chalmers RM, Katzer F. Looking for Cryptosporidium: the application of advances in detection and diagnosis. *Trends Parasitol*. 2013;29(5):237–51.
6. Goodgame RW et al. Intestinal function and injury in acquired immunodeficiency syndrome-related cryptosporidiosis. *Gastroenterology*. 1995;108(4):1075–82.
7. Zhang Y et al. Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and cryptosporidium. Diarrhea Working Group, Peru. *J Pediatr Gastroenterol Nutr*. 2000;31(1):16–21.
8. Pantenburg B et al. Intestinal immune response to human *Cryptosporidium* sp. infection. *Infect Immun*. 2008;76(1):23–9.
9. Hernandez J et al. Substance P is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis. *Infect Immun*. 2007;75(3):1137–43.
10. Scallan E et al. Foodborne illness acquired in the United States—major pathogens. *Emerg Infect Dis*. 2011;17(1):7–15.
11. Painter JE et al. Cryptosporidiosis surveillance—United States, 2011–2012. *MMWR Surveill Summ*. 2015;64 Suppl 3:1–14.

12. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. *Curr Opin Infect Dis.* 2012;25(5):555–63.
- 13.●● Kotloff KL et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet.* 2013;382(9888):209–22. **This reports the results of a multicenter study of childhood diarrhea from 7 countries in SubSaharan Africa and South Asia. It highlighted the role of *Cryptosporidium* as second to rotavirus as a cause of moderate to severe diarrhea and death among children under 2 years of age.**
- 14.●● Liu J et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. *Lancet Infect Dis.* 2014;14(8):716–24. **This multicenter study compared multiplex PCR, film array, and bead arrays assays for multiple pathogens. Overall, it demonstrated that each of the techniques was highly reproducible and demonstrated that *Cryptosporidium* was underdiagnosed even using specimens from the GEMS study.**
15. Moore SR et al. Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. *Gastroenterology.* 2010;139(4):1156–64.
16. Guerrant DI et al. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four–seven years later in a poor urban community in northeast Brazil. *Am J Trop Med Hyg.* 1999;61(5):707–13.
17. Mondal D et al. Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. *Clin Infect Dis.* 2012;54(2):185–92.
18. Molbak K et al. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, West Africa. *Am J Clin Nutr.* 1997;65(1):149–52.
19. Guerrant RL et al. The impoverished gut—a triple burden of diarrhoea, stunting and chronic disease. *Nat Rev Gastroenterol Hepatol.* 2013;10(4):220–9.
20. Costa LB et al. Cryptosporidium-malnutrition interactions: mucosal disruption, cytokines, and TLR signaling in a weaned murine model. *J Parasitol.* 2011;97(6):1113–20.
21. Checkley W et al. Effects of *Cryptosporidium parvum* infection in Peruvian children: growth faltering and subsequent catch-up growth. *Am J Epidemiol.* 1998;148(5):497–506.
22. Cabada MM, White Jr AC. Treatment of cryptosporidiosis: do we know what we think we know? *Curr Opin Infect Dis.* 2010;23(5):494–9.
23. Masur H et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis.* 2014;58(9):1308–11.
24. Dillingham RA et al. High early mortality in patients with chronic acquired immunodeficiency syndrome diarrhea initiating antiretroviral therapy in Haiti: a case-control study. *Am J Trop Med Hyg.* 2009;80(6):1060–4.
25. Mele R et al. Indinavir reduces *Cryptosporidium parvum* infection in both in vitro and in vivo models. *Int J Parasitol.* 2003;33(7):757–64.
26. Amadi B et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. *Lancet.* 2002;360(9343):1375–80.
27. Rossignol JF et al. Effect of nitazoxanide in diarrhea and enteritis caused by *Cryptosporidium* species. *Clin Gastroenterol Hepatol.* 2006;4(3):320–4.
28. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by *Cryptosporidium parvum*: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. *J Infect Dis.* 2001;184(1):103–6.
29. Amadi B et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. *BMC Infect Dis.* 2009;9:195.
30. Hussien SM et al. Comparative study between the effect of nitazoxanide and paromomycine in treatment of cryptosporidiosis in hospitalized children. *J Egypt Soc Parasitol.* 2013;43(2):463–70.
31. Raja K et al. Prevalence of cryptosporidiosis in renal transplant recipients presenting with acute diarrhea at a single center in Pakistan. *J Nephropathol.* 2014;3(4):127–31.
32. Danziger-Isakov L. Gastrointestinal infections after transplantation. *Curr Opin Gastroenterol.* 2014;30(1):40–6.
33. Bhadauria D et al. Cryptosporidium infection after renal transplantation in an endemic area. *Transpl Infect Dis.* 2015;17(1):48–55.
34. Legrand F et al. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. *Bone Marrow Transplant.* 2011;46(6):858–62.
35. Bonatti H et al. Cryptosporidium enteritis in solid organ transplant recipients: multicenter retrospective evaluation of 10 cases reveals an association with elevated tacrolimus concentrations. *Transpl Infect Dis.* 2012;14(6):635–48.
36. Krause I et al. Cryptosporidiosis in children following solid organ transplantation. *Pediatr Infect Dis J.* 2012;31(11):1135–8.
37. Fan X et al. CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. *Clin Immunol.* 2012;143(2):152–61.
38. Hashmey R et al. Cryptosporidiosis in Houston, Texas. A report of 95 cases. *Medicine (Baltimore).* 1997;76(2):118–39.
39. Hewitt RG et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. *AIDS Clinical Trial Group. Clin Infect Dis.* 2000;31(4):1084–92.
40. White Jr AC et al. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. *J Infect Dis.* 1994;170(2):419–24.
41. Allam AF, Shehab AY. Efficacy of azithromycin, praziquantel and mirazid in treatment of cryptosporidiosis in school children. *J Egypt Soc Parasitol.* 2002;32(3):969–78.
42. Smith NH et al. Combination drug therapy for cryptosporidiosis in AIDS. *J Infect Dis.* 1998;178(3):900–3.
43. Giacometti A et al. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against *Cryptosporidium parvum* in cell culture. *J Antimicrob Chemother.* 2000;45(4):453–6.
44. Holmberg SD et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. *HIV Outpatient Study (HOPS) Investigators. JAMA.* 1998;279(5):384–6.
45. Fichtenbaum CJ et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. *AIDS.* 2000;14(18):2889–93.
46. Amenta M et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in *Cryptosporidium parvum* and *Blastocystis hominis* infections. *J Chemother.* 1999;11(5):391–5.
47. Gathe Jr JC et al. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. *J Acquir Immune Defic Syndr.* 2008;48(3):363–4.
48. Kothavade RJ. Challenges in understanding the immunopathogenesis of Cryptosporidium infections in humans. *Eur J Clin Microbiol Infect Dis.* 2011;30(12):1461–72.
49. Feng H et al. Bile acids enhance invasiveness of *Cryptosporidium* spp. into cultured cells. *Infect Immun.* 2006;74(6):3342–6.
50. Yang YL, Buck GA, Widmer G. Cell sorting-assisted microarray profiling of host cell response to *Cryptosporidium parvum* infection. *Infect Immun.* 2010;78(3):1040–8.

51. Castellanos-Gonzalez A et al. Human primary intestinal epithelial cells as an improved in vitro model for *Cryptosporidium parvum* infection. *Infect Immun*. 2013;81(6):1996–2001.
52. Murphy RC et al. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from *C. parvum* and *T. gondii*. *ACS Med Chem Lett*. 2010;1(7):331–5.
53. Castellanos-Gonzalez A et al. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. *J Infect Dis*. 2013;208(8):1342–8.
54. Na BK et al. Cryptopain-1, a cysteine protease of *Cryptosporidium parvum*, does not require the pro-domain for folding. *Parasitology*. 2009;136(2):149–57.
55. Ndao M et al. A cysteine protease inhibitor rescues mice from a lethal *Cryptosporidium parvum* infection. *Antimicrob Agents Chemother*. 2013;57(12):6063–73.
56. Kumar VP et al. Structural studies provide clues for analog design of specific inhibitors of *Cryptosporidium hominis* thymidylate synthase-dihydrofolate reductase. *Bioorg Med Chem Lett*. 2014;24(17):4158–61.
57. Sun Z et al. Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole *Cryptosporidium parvum* inosine 5'-monophosphate dehydrogenase (CpIMPDH) inhibitors. *J Med Chem*. 2014;57(24):10544–50.
58. Gorla SK et al. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. *Antimicrob Agents Chemother*. 2014;58(3):1603–14.
59. Jefferies R et al. Target validation of the inosine monophosphate dehydrogenase (IMPDH) gene in *Cryptosporidium* using Phylomer(R) peptides. *Exp Parasitol*. 2015;148:40–8.
60. Bessoff K et al. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block *Cryptosporidium parvum* growth. *Antimicrob Agents Chemother*. 2013;57(4):1804–14.
61. Spangenberg T et al. The open access malaria box: a drug discovery catalyst for neglected diseases. *PLoS One*. 2013;8(6), e62906.
62. Bessoff K et al. Identification of *Cryptosporidium parvum* active chemical series by repurposing the open access malaria box. *Antimicrob Agents Chemother*. 2014;58(5):2731–9.
63. Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. *Gut Microbes*. 2013;4(1):66–71.
64. Castro IC et al. Arginine decreases *Cryptosporidium parvum* infection in undernourished suckling mice involving nitric oxide synthase and arginase. *Nutrition*. 2012;28(6):678–85.
65. Costa LB et al. Novel in vitro and in vivo models and potential new therapeutics to break the vicious cycle of *Cryptosporidium* infection and malnutrition. *J Infect Dis*. 2012;205(9):1464–71.
66. Kandil HM, Berschneider HM, Argenzio RA. Tumour necrosis factor alpha changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins. *Gut*. 1994;35(7):934–40.